Tetraph Pharma (TTPH) Misses Q2 EPS by 17c

Tetraph Pharma (NASDAQ: TTPH) reported Q2 EPS of ($0.71), $0.17 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $2.79 million.

For earnings history and earnings-related data on Tetraph Pharma (TTPH) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Ideal Power (IPWR) Tops Q2 EPS by 2c
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02